pharmaceutical stocks

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With...

Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17....

Congressman Bernie Sanders (I-Vt.) has been known to tussle with public companies over their high prices or anticompetitive behavior, including pharmaceutical companies and their high costs. In his newest battle, Sanders is taking on the growing popularity of weight-loss drugs and diabetes...

The ruling by the U.S. Supreme Court to overturn Roe v. Wade and leave the decision of abortion to the states has been a big topic over the last few days. An analyst singles out a pharmaceutical company that could benefit from increased purchases of over-the-counter contraceptives. The Perrigo...

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more future initiatives. Here is a look at stocks to watch after the State of the Union address....

It's a great time to invest in pharmaceutical companies such as AbbVie Inc (NYSE: ABBV), Cerity Partners' Jim Lebenthal shared Wednesday on CNBC's "Fast Money Halftime Report." Lebenthal told CNBC that he is slowly building the pharmaceutical portion of his...

Analysts at Goldman Sachs turned bearish on industry giant Johnson & Johnson (NYSE: JNJ) amid valuation concerns. Analyst Jami Rubin downgraded J&J's stock from Neutral to Sell with a price target boosted from $125 to $130, which implies downside from Wednesday's open of $133.25....

Analysts at Cantor Fitzgerald turned incrementally bullish on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after the once-troubled pharmaceutical company is showing signs of sustaining momentum. Cantor Fitzgerald's Louise Chen maintains an Overweight rating on Valeant's stock with a price...

JPMorgan's Michael Weinstein upgraded shares of Johnson & Johnson (NYSE: JNJ) from Neutral to Overweight with a price target boosted from $133 to $140 despite underperformance over the past year. According to Weinstein, shares of JNJ have underperformed the past 12 months and showed investors...

Sarepta Therapeutics Inc's (NYSE: SRPT) rough Tuesday carried over into Wednesday's session after the company reported a better than expected loss in its fourth quarter but expects full year sales of Exondys to fall short of what analysts were expecting. Brian Skorney of Baird commented in...

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plunged more than 15 percent Monday morning and hit a new 52-week low of $109.80 after the company's board of directors announced CEO David Hallal will leave the company amid an ongoing audit and finance committee investigation. The company's...

Gary Nachman of BMO Capital Markets has some good news and bad news for Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s investors following the company's third-quarter earnings report. The good news is that Valeant's new segment reporting could provide greater visibility on its business outlook. The...

Pharmaceutical investors could breathe a sigh of relief after Donald Trump won the race to the White House, at least according to Alex Arfaei of BMO Capital Markets. Arfaei commented in a research report on Wednesday that a Trump presidency, coupled with a Republican Congress and the apparent...

Voting for the U.S. presidential election is underway and one group of investors couldn't be more relieved that the end is in sight. As noted by Gadfly's Max Nisen, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has fallen 23 percent year-to-date while the Bloomberg...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) soared Tuesday after The Wall Street Journal reported the company is in talks to sell its Salix unit for up to $10 billion. Salix, a leader in the gastrointestinal market, was acquired by Valeant back in February 2015 for $158 per share,...